A weight-loss drug cut heart attacks in people who didn't have diabetes
Weekly semaglutide reduced major cardiovascular events by roughly 20% in adults with obesity and established heart disease but no diabetes.
The Weekly Signal
All editions →Medicine, biology, public health, neuroscience, and human wellbeing.
Weekly semaglutide reduced major cardiovascular events by roughly 20% in adults with obesity and established heart disease but no diabetes.